Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | 30 Months Ended | 36 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|
Sep. 27, 2026 |
Sep. 28, 2025 |
Sep. 27, 2026 |
Sep. 28, 2025 |
Sep. 27, 2026 |
Sep. 27, 2026 |
|||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Restructuring charges | [1] | $ 753.0 | $ 237.0 | $ 1,221.0 | $ 784.0 | |||
| Productivity and Operational Efficiencies [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Restructuring charges | 38.0 | |||||||
| Biopharma [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Restructuring charges | 461.0 | 240.0 | 882.0 | 451.0 | ||||
| Realigning Our Cost Base Program [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 7,300.0 | 7,300.0 | $ 7,300.0 | $ 7,300.0 | ||||
| Restructuring cost incurred to date | 5,700.0 | 5,700.0 | 5,700.0 | 5,700.0 | ||||
| Realigning Our Cost Base Program [Member] | Biopharma [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 4,800.0 | 4,800.0 | 4,800.0 | 4,800.0 | ||||
| Restructuring cost incurred to date | 4,300.0 | 4,300.0 | 4,300.0 | 4,300.0 | ||||
| Restructuring charges | 385.0 | 107.0 | 849.0 | 669.0 | 3,700.0 | |||
| Realigning Our Cost Base Program - Initial Phase [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 4,700.0 | 4,700.0 | 4,700.0 | 4,700.0 | ||||
| Realigning Our Cost Base Program - Initial Phase [Member] | Biopharma [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 3,400.0 | 3,400.0 | 3,400.0 | 3,400.0 | ||||
| Realigning Our Cost Base Program - Productivity Enhancements | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 2,000.0 | 2,000.0 | 2,000.0 | 2,000.0 | ||||
| Realigning Our Cost Base Program - Productivity Enhancements | Biopharma [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 800.0 | 800.0 | 800.0 | 800.0 | ||||
| Realigning Our Cost Base Program - Research and Development [Member] | Biopharma [Member] | Productivity and Operational Efficiencies [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 600.0 | 600.0 | 600.0 | 600.0 | ||||
| Manufacturing Optimization Program [Member] | Biopharma [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 5,400.0 | 5,400.0 | 5,400.0 | 5,400.0 | ||||
| Restructuring cost incurred to date | 1,200.0 | 1,200.0 | 1,200.0 | 1,200.0 | ||||
| Restructuring charges | 65.0 | $ 117.0 | 14.0 | $ (295.0) | 889.0 | |||
| Manufacturing Optimization Program - Phase One [Member] | Biopharma [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | 1,400.0 | 1,400.0 | 1,400.0 | 1,400.0 | ||||
| Manufacturing Optimization Program - Next Phase [Member] | Biopharma [Member] | ||||||||
| Restructuring Cost and Reserve [Line Items] | ||||||||
| Expected restructuring cost | $ 4,000.0 | $ 4,000.0 | $ 4,000.0 | $ 4,000.0 | ||||
| Non-cash expenditures, percentage of expected cost | 60.00% | 60.00% | 60.00% | 60.00% | ||||
| Cash expenditures, percentage of expected cost | 40.00% | 40.00% | 40.00% | 40.00% | ||||
| ||||||||